Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A

Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.

Mesa RA, Hanson CA, Ketterling RP, Schwager S, Knudson RA, Tefferi A

5-Azacitidine has limited therapeutic activity in myelofibrosis.

Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A

BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis.

Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ

Bortezomib therapy in myelofibrosis: a phase II clinical trial.

Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A

Risk factors for leukemic transformation in patients with primary myelofibrosis.

Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A

The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.

Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.

Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.

Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A